Theravance Biopharma (TBPH) Total Non-Current Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Total Non-Current Liabilities data on file, last reported at $472.1 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 37.91% year-over-year to $472.1 million in Q1 2026; TTM through Mar 2026 was $472.1 million, a 37.91% increase from a year earlier, with the FY2025 full-year figure at $485.3 million, up 79.42% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $472.1 million, down from $485.3 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for TBPH reached as high as $700.8 million in Q3 2022 and fell as low as $270.5 million in Q4 2024.
• Historically, Total Non-Current Liabilities has averaged $418.0 million across 5 years, with a median of $405.9 million in 2023.
• Across the five-year window, Total Non-Current Liabilities slumped 43.07% in 2023 and jumped 79.42% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $531.4 million in 2022, then plunged by 43.07% to $302.5 million in 2023, then retreated by 10.6% to $270.5 million in 2024, then jumped by 79.42% to $485.3 million in 2025, then dropped by 2.72% to $472.1 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $472.1 million in Q1 2026, $485.3 million in Q4 2025, and $415.1 million in Q3 2025.